Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 241 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Durect Corp | DRRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.0354 | -4.20% | 0.808 | 07:07:01 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.8434 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 5 | 241 | - | 0.4703 - 7.46 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:04:02 | 1 | $ 0.8731 | USD |
Durect Corp Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 25.06M | 29.83M | - | 8.55M | -27.62M | -0.93 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Durect News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical DRRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.7889 | 0.946 | 0.77 | 0.8728307 | 91,208 | 0.0191 | 2.42% |
| 1 Month | 1.27 | 1.34 | 0.7235 | 0.9780758 | 127,300 | -0.462 | -36.38% |
| 3 Months | 0.795 | 1.41 | 0.6802 | 1.00 | 167,743 | 0.013 | 1.64% |
| 6 Months | 2.50 | 3.14 | 0.4703 | 0.8150741 | 460,962 | -1.69 | -67.68% |
| 1 Year | 4.40 | 7.46 | 0.4703 | 1.73 | 345,950 | -3.59 | -81.64% |
| 3 Years | 17.70 | 19.30 | 0.4703 | 7.01 | 475,749 | -16.89 | -95.44% |
| 5 Years | 5.79 | 41.00 | 0.4703 | 15.52 | 782,129 | -4.98 | -86.04% |
Durect Description
| Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the United States. |
